Last reviewed 2026-04-20 · How we verify

Paveril (dioxyline)

unknown active

Paveril (generic name: dioxyline) is a dioxyline drug. It is currently in unknown development.

Paveril works by blocking an enzyme called methionine aminopeptidase 2, which is crucial for cancer cells to grow and multiply.

Paveril (dioxyline) is a small molecule drug that targets methionine aminopeptidase 2 (MetAP2), an enzyme involved in protein synthesis. It is a member of the dioxyline class and its exact commercial status is unknown. Paveril's mechanism of action involves inhibiting MetAP2, which is essential for cancer cell growth and survival. However, its clinical use and safety profile are not well established. Further research is needed to determine its potential as a therapeutic agent.

At a glance

Generic name	dioxyline
Drug class	dioxyline
Target	Methionine aminopeptidase 1, Methionine aminopeptidase 2
Therapeutic area	Oncology
Phase	unknown

Mechanism of action

Think of it like a roadblock: Paveril stops cancer cells from making the proteins they need to grow and divide. This can help slow down or even stop the growth of cancer tumors. By targeting this specific enzyme, Paveril aims to disrupt the cancer cells' ability to survive and thrive.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Paveril CI brief — competitive landscape report
Paveril updates RSS · CI watch RSS
portfolio CI

Frequently asked questions about Paveril

What is Paveril?

Paveril (dioxyline) is a dioxyline drug.

How does Paveril work?

Paveril works by blocking an enzyme called methionine aminopeptidase 2, which is crucial for cancer cells to grow and multiply.

What is the generic name of Paveril?

dioxyline is the generic (nonproprietary) name of Paveril.

What drug class is Paveril in?

Paveril belongs to the dioxyline class. See all dioxyline drugs at /class/dioxyline.

What development phase is Paveril in?

Paveril is in unknown.

What does Paveril target?

Paveril targets Methionine aminopeptidase 1, Methionine aminopeptidase 2 and is a dioxyline.

Drug class: All dioxyline drugs
Target: All drugs targeting Methionine aminopeptidase 1, Methionine aminopeptidase 2
Manufacturer: — full pipeline
Therapeutic area: All drugs in Oncology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing